Journal Mobile Options
Table of Contents
Vol. 16, No. 1, 2003
Issue release date: May 2003
Section title: Original Paper
Cerebrovasc Dis 2003;16:36–41
(DOI:10.1159/000070113)

Noninvasive Monitoring of Cerebral Oxygenation during Vasomotor Reactivity Tests by a New Near-Infrared Spectroscopy Device

Terborg C. · Birkner T. · Schack B. · Weiller C. · Röther J.
aDepartment of Neurology and bInstitute of Medical Statistics, Computer Science and Documentation, University of Jena, Jena, cDepartment of Neurology, University Hospital Eppendorf, Hamburg, Germany

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 8/19/2002
Accepted: 8/26/2002
Published online: 5/16/2003

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 2

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: http://www.karger.com/CED

Abstract

Background: Spatially resolved spectroscopy is a recently developed technique for noninvasive monitoring of cerebral tissue oxygenation using the photon diffusion theory. Methods: We studied this technique with a new, commercial near-infrared spectroscopy (NIRS) device during vasomotor reactivity tests in 28 healthy volunteers (mean age 31.0 years; SD 10.6 years) and compared it with values assessed by the modified Beer-Lambert law and indices from simultaneous transcranial Doppler sonography of both middle cerebral arteries. We measured O2 reactivity as percentage change of cerebral blood flow velocity (CBFV), as absolute change in the concentrations (measured in µmol/l) of oxygenated (HbO2), deoxygenated (Hb) and total hemoglobin (HbT), and as change in the tissue oxygenation index (TOI) during inhalation of 100% oxygen. CO2 reactivity was calculated as percentage change of CBFV (NCR), as absolute change in the concentrations of HbO2, Hb, and HbT (µmol/l), and as change in TOI (%) per 1% increase in end-tidal CO2. Results: One hundred percent oxygen inhalation lead to a decrease in CBFV (mean ± SD: left –8.0 ± 7.0%, p = 0.000; right –9.6 ± 7.6%, p = 0.000), an increase in HbO2 (0.99 ± 1.07 µmol/l), Hbdiff (2.23 ± 1.72 µmol/l), and TOI (3.1 ± 1.5%), and a decrease in Hb (–1.22 ± 0.74 µmol/l), significant from baseline values (p = 0.0000). CO2 reactivity was: NCR left 25.4 ± 14.7%; NCR right 25.9 ± 13.4%; HbO2 1.99 ± 0.97 µmol/l; Hb –1.24 ± 0.81 µmol/l; HbT 0.81 ± 1.0 µmol/l, and TOI 3.7 ± 2.2%. O2 reactivity in TCD did not correlate with NIRS reactivities (Pearson p > 0.05), but NCR did correlate with changes in HbO2, Hb, and TOI (Pearson p < 0.01). TOI was closely related to indices derived from the Beer-Lambert law (Pearson p < 0.03), but not with mean arterial blood pressure or skin blood flow during vasomotor reactivity tests. Conclusion: Spatially resolved spectroscopy provides an encouraging, noninvasive new tool to study cerebral tissue oxygenation during vasomotor reactivity tests consistent with physiological changes.


  

Author Contacts

Christoph Terborg, MD
Department of Neurology, Friedrich Schiller University of Jena
Philosophenweg 3
D–07740 Jena (Germany)
Tel./Fax +49 3641 935 410, E-Mail Christoph.Terborg@med.uni-jena.de

  

Article Information

Received: July 19, 2001
Accepted: August 19, 2002
Number of Print Pages : 6
Number of Figures : 2, Number of Tables : 2, Number of References : 45

  

Publication Details

Cerebrovascular Diseases (Official Journal of the European Stroke Council)

Vol. 16, No. 1, Year 2003 (Cover Date: Released May 2003)

Journal Editor: J. Bogousslavsky, Lausanne; M.G. Hennerici, Mannheim
ISSN: 1015–9770 (print), 1421–9786 (Online)

For additional information: http://www.karger.com/journals/ced


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: 8/19/2002
Accepted: 8/26/2002
Published online: 5/16/2003

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 2

ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)

For additional information: http://www.karger.com/CED


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.